Interpace Biosciences, Inc. (IDXG)

Market Cap	39.34M +910.6%
Revenue (ttm)	36.14M -20.5%
Net Income	24.45M +435.6%
EPS	0.89 +24.1%
Shares Out	27.70M
PE Ratio	1.57
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,420
Open	7.10
Previous Close	7.10
Day's Range	7.10 - 7.85
52-Week Range	0.77 - 7.25
Beta	0.61
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and cha...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1986
• Employees: 102
• Stock Exchange: OTCMKTS
• Ticker Symbol: IDXG

Financial Performance

In 2025, Interpace Biosciences's revenue was $38.73 million, a decrease of -17.47% compared to the previous year's $46.93 million. Earnings were $24.58 million, an increase of 293.96%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 27, 2026

Data Sources Report a data error